Collaboration to create novel antibody drug candidates using Chugai's proprietary antibody engineering technologies for drug targets identified through Gero's AI-driven human data-first platform ...

Gero's physics-first AI drug discovery platform is transforming breakthroughs in the physics of aging into a pipeline of medicines designed to treat age-related diseases and slow the aging process ...

Add Yahoo as a preferred source to see more of our stories on Google. "Twenty years ago, my first real job in television was as a Story Editor on Stargate: Atlantis. I spent five years at the ...

Funding by Melnichek Investments fuels Gero’s strategy to apply AI and real-world human health data to decode the relationship between aging and diseases, unravel their root causes, and create ...

Following a Chugai (Roche Group) collaboration with up to $250M in milestones in addition to royalties, and inspired by mammals that defy the rules of aging, Gero uses physics-first AI and human ...

People who know Naledi are perpetually aware of two things: he is a talented visual artist, and he has seen copious amounts of anime. Dr. Gero's family, including his wife Vomi and grandson Dr. Hedo, ...

Gero raised $17 million in new financing to advance its AI-driven drug discovery platform focused on aging and chronic disease. The AI-driven biotech company applies physics-based models to aging and ...

TOKYO, July 07, 2025 (GLOBE NEWSWIRE) -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519, hereafter "Chugai"), and Gero PTE. LTD. (hereafter "Gero"), a Singapore-based biotechnology company, announced ...